This Zenith job posting for a Senior Director of Clinical Operations is a very positive sign that Zenith Epigenetics is moving their program(s) into the clinical stage. From yesterday's Zenith NR:
"We extend our gratitude to Dr. Johann for guiding Zenith from its initial days as a newly-incorporated company to today as we embark on our investigational new drug application (IND) for our lead BET bromodomain inhibitor in oncology."
The Zenith website still reads "Zenith is targeting the second half of 2015 to file an IND for hematological malignancies and solid tumors."
Masila posted some good info from the Zenith special meeting on June 30th that exemplifies the positive outlook for Zenith. However, this was from 5 months ago and with only 30 days left in 2015 it is still possible to see some additional announcements from Zenith (such as filing the IND, or announcment of an upcoming IPO to be completed in 2016); however, highly unlikely if not impossible IMO in the next 30 days that any IPO is complete or that any clinical trial is started.
BearDownAZ